CNL
MCID: CHR286
MIFTS: 42

Chronic Neutrophilic Leukemia (CNL)

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Chronic Neutrophilic Leukemia

MalaCards integrated aliases for Chronic Neutrophilic Leukemia:

Name: Chronic Neutrophilic Leukemia 12 52 58 15 17 71
Leukemia Neutrophilic Chronic 54
Cnl 52

Characteristics:

Orphanet epidemiological data:

58
chronic neutrophilic leukemia
Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0080187
NCIt 49 C3179
MESH via Orphanet 44 D015467
ICD10 via Orphanet 33 D47.1
UMLS via Orphanet 72 C0023481
Orphanet 58 ORPHA86829
UMLS 71 C0023481

Summaries for Chronic Neutrophilic Leukemia

Disease Ontology : 12 A chronic leukemia characterized by neutrophilic leukocytosis with no detectable Philadelphia chromosome or BCR/ABL fusion gene.

MalaCards based summary : Chronic Neutrophilic Leukemia, also known as leukemia neutrophilic chronic, is related to polycythemia and splenomegaly. An important gene associated with Chronic Neutrophilic Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Pathways in cancer. The drugs Ketamine and Dextromethorphan have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm that features a persistent... more...

Related Diseases for Chronic Neutrophilic Leukemia

Diseases related to Chronic Neutrophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
# Related Disease Score Top Affiliating Genes
1 polycythemia 30.3 TET2 JAK2 CALR
2 splenomegaly 30.2 SETBP1 JAK2 IFNA2 IFNA1
3 refractory anemia 29.9 TET2 CSF3 ASXL1
4 severe congenital neutropenia 29.9 JAK2 CSF3R CSF3
5 neutropenia 29.9 IFNA2 IFNA1 CSF3R CSF3
6 leukemia 29.3 U2AF1 TET2 KMT2A JAK2 CSF3R ASXL1
7 myeloproliferative neoplasm 29.1 U2AF1 TET2 LUC7L2 KMT2A JAK2 IFNA2
8 pancytopenia 29.0 U2AF1 LUC7L2 KMT2A CSF3 CD34
9 acute leukemia 28.9 SETBP1 KMT2A JAK2 CSF3R CSF3 CD34
10 neutrophilia, hereditary 28.9 U2AF1 SETBP1 LUC7L2 JAK2 CSF3R CSF3
11 myeloma, multiple 28.8 U2AF1 JAK2 IFNA1 CSF3 CD34 ABL1
12 thrombocytopenia 28.5 U2AF1 JAK2 IFNA2 IFNA1 CSF3 CD34
13 thrombocytosis 28.4 U2AF1 TET2 JAK2 IFNA1 CSF3 CALR
14 myeloid leukemia 28.1 U2AF1 TET2 KMT2A JAK2 CSF3R CSF3
15 leukemia, acute lymphoblastic 28.0 U2AF1 KMT2A JAK2 CSF3R CSF3 CD34
16 atypical chronic myeloid leukemia 27.8 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 JAK2
17 chronic myelomonocytic leukemia 27.5 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 KMT2A
18 polycythemia vera 27.3 U2AF1 TET2 JAK2 IFNA2 IFNA1 CSF3R
19 leukemia, chronic myeloid 27.1 U2AF1 SETBP1 LUC7L2 KMT2A JAK2 IFNA2
20 myelofibrosis 27.0 U2AF1 TET2 SRSF2 SETBP1 JAK2 IFNA2
21 essential thrombocythemia 26.9 U2AF1 TET2 JAK2 IFNA2 IFNA1 CSF3
22 myelodysplastic/myeloproliferative neoplasm 26.7 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 KMT2A
23 leukemia, chronic lymphocytic 26.7 U2AF1 TET2 SRSF2 KMT2A JAK2 IFNA1
24 myelodysplastic syndrome 26.4 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 KMT2A
25 leukemia, acute myeloid 25.9 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 KMT2A
26 neutropenia, severe congenital, 3, autosomal recessive 10.3 CSF3R CSF3
27 engraftment syndrome 10.3 IFNA1 CSF3
28 plasma cell neoplasm 10.3
29 bladder cancer 10.3
30 mechanical ectropion 10.3 IFNA2 CD34
31 corneal intraepithelial neoplasm 10.2 IFNA2 IFNA1
32 lymphomatoid granulomatosis 10.2 IFNA2 IFNA1
33 cryoglobulinemia, familial mixed 10.2 IFNA2 IFNA1
34 secondary corneal edema 10.2 IFNA2 IFNA1
35 retinitis pigmentosa and erythrocytic microcytosis 10.1 JAK2 CSF3
36 monoclonal gammopathy of uncertain significance 10.1
37 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
38 graft-versus-host disease 10.1
39 central nervous system leukemia 10.1
40 chronic graft versus host disease 10.1
41 conjunctival squamous cell carcinoma 10.1 IFNA2 IFNA1
42 mental retardation, autosomal dominant 29 10.1 SETBP1 ABL1
43 myeloid sarcoma 10.1 U2AF1 KMT2A CD34
44 patau syndrome 10.1 U2AF1 SRSF2 ASXL1
45 discoid lupus erythematosus 10.1 IFNA2 IFNA1
46 systemic mastocytosis with associated hematologic neoplasm 10.0 TET2 SRSF2 ASXL1
47 childhood acute myeloid leukemia 10.0 TET2 SETBP1 ASXL1
48 squamous papillomatosis 10.0 IFNA2 IFNA1
49 core binding factor acute myeloid leukemia 10.0 JAK2 CSF3
50 gastroenteritis 10.0 IFNA2 IFNA1 CSF3

Graphical network of the top 20 diseases related to Chronic Neutrophilic Leukemia:



Diseases related to Chronic Neutrophilic Leukemia

Symptoms & Phenotypes for Chronic Neutrophilic Leukemia

GenomeRNAi Phenotypes related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

26 (show all 42)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.08 IFNA1 IFNA2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.08 CSF3R
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.08 CSF3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-111 10.08 KMT2A
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.08 CSF3R
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.08 IFNA2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.08 KMT2A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.08 CSF3R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.08 CSF3R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-14 10.08 IFNA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.08 IFNA1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.08 CSF3R
13 Increased shRNA abundance (Z-score > 2) GR00366-A-148 10.08 CSF3 CSF3R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.08 ABL1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.08 ABL1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.08 LUC7L2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.08 CSF3R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-167 10.08 IFNA2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.08 IFNA1 CSF3R IFNA2 KMT2A
20 Increased shRNA abundance (Z-score > 2) GR00366-A-175 10.08 IFNA1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.08 IFNA2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.08 LUC7L2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.08 CSF3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-209 10.08 IFNA1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.08 CSF3R
26 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.08 ABL1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.08 IFNA2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.08 IFNA2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.08 ABL1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.08 ABL1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.08 ABL1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.08 ABL1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-61 10.08 IFNA1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-62 10.08 IFNA2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.08 KMT2A
36 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.08 IFNA1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.08 IFNA1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.08 IFNA1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.08 CSF3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.08 ABL1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.08 KMT2A
42 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.08 KMT2A

Drugs & Therapeutics for Chronic Neutrophilic Leukemia

Drugs for Chronic Neutrophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
3
Acyclovir Approved Phase 3 59277-89-3 2022
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
6
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
7
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
8
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
9
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
10
Polyestradiol phosphate Approved Phase 3 28014-46-2
11
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
12 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
13 Anesthetics, Dissociative Phase 3
14 Neurotransmitter Agents Phase 3
15 Liver Extracts Phase 3
16 Cola Phase 3
17 Analgesics, Opioid Phase 3
18 Antiprotozoal Agents Phase 3
19 Antiparasitic Agents Phase 3
20 Excitatory Amino Acid Antagonists Phase 3
21 Narcotics Phase 3
22 Analgesics Phase 3
23 valacyclovir Phase 3
24 Anesthetics Phase 3
25 Anesthetics, General Phase 3
26 Anesthetics, Intravenous Phase 3
27 Amebicides Phase 3
28 Liposomal amphotericin B Phase 3
29 Estradiol 17 beta-cypionate Phase 3
30 Contraceptives, Oral Phase 3
31 Contraceptive Agents Phase 3
32 Contraceptives, Oral, Combined Phase 3
33 Estradiol 3-benzoate Phase 3
34 Norgestimate, ethinyl estradiol drug combination Phase 3
35
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
36
alemtuzumab Approved, Investigational Phase 2 216503-57-0
37
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
38
Caspofungin Approved Phase 2 162808-62-0, 179463-17-3 2826718 468682
39
Promethazine Approved, Investigational Phase 2 60-87-7 4927
40
Acetaminophen Approved Phase 2 103-90-2 1983
41
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
42
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
43
Benzyl alcohol Approved Phase 2 100-51-6 244
44
Venetoclax Approved, Investigational Phase 1, Phase 2 1257044-40-8 49846579
45
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
46
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
47
Melphalan Approved Phase 2 148-82-3 460612 4053
48
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
49
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
50
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 112)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
3 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
4 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
5 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
6 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
7 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
8 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
9 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
10 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
11 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
12 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
14 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
15 Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R Completed NCT02092324 Phase 2 Ruxolitinib Phosphate
16 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
17 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
18 A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
19 Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
20 Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors Completed NCT00005622 Phase 2 cyclophosphamide
21 Conditioning With Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Allogeneic Marrow or Peripheral Blood Stem Cell (PBSC) Transplantation for Myelodysplasia and Myeloproliferative Disorders Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
22 Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
23 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
24 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
25 A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
26 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
27 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
28 A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
29 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
30 Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
31 HLA Matched Related and Unrelated Bone Marrow Transplantation With Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide for Hematological Malignancies Completed NCT00134017 Phase 2 Busulfan;Cyclophosphamide
32 Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
33 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
34 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
35 Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
36 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
37 A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AML Recruiting NCT03862157 Phase 1, Phase 2 Azacitidine;Pevonedistat;Venetoclax
38 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
39 A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
40 Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01159067 Phase 2 deferasirox
41 A Phase I/II Study of Double Unit Umbilical Cord Blood (UCB) Transplantation Utilizing Graft Administration Via Intra-Bone Marrow Injection (Companion Protocol to MT2000-25) Terminated NCT00295880 Phase 1, Phase 2
42 Conditioning for Graft Failure After Hematopoietic Stem Cell Transplantation Terminated NCT00617929 Phase 2 clofarabine
43 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
44 A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
45 Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
46 Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation Withdrawn NCT00301912 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
47 Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (CRBSI) Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
48 T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation Withdrawn NCT00816413 Phase 1, Phase 2 cyclosporine;mycophenolate mofetil;pentostatin
49 Emergency Access to C.V. pp65 / IE-1 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistant or Therapy Refractory Infections Unknown status NCT00769613 Phase 1
50 Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study Completed NCT01484015 Phase 1 cefepime hydrochloride

Search NIH Clinical Center for Chronic Neutrophilic Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thioguanine

Genetic Tests for Chronic Neutrophilic Leukemia

Anatomical Context for Chronic Neutrophilic Leukemia

MalaCards organs/tissues related to Chronic Neutrophilic Leukemia:

40
Neutrophil, Bone, Bone Marrow, Myeloid, T Cells, Liver, Nk Cells

Publications for Chronic Neutrophilic Leukemia

Articles related to Chronic Neutrophilic Leukemia:

(show top 50) (show all 263)
# Title Authors PMID Year
1
Neutrophil function and cytokine-specific signaling in chronic neutrophilic leukemia. 61 54
18241214 2009
2
FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4;11)(q21;q23). 61 54
14999297 2004
3
Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. 54 61
12393423 2003
4
Serum G-CSF levels in primary myelofibrosis and chronic neutrophilic leukemia as estimated by the highly sensitive chemiluminescence enzyme immunoassay (CLEIA). 61 54
8882966 1996
5
Chronic neutrophilic leukemia, a rare case of leukocytosis. 61
32447046 2020
6
Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation. 61
32577845 2020
7
A population-based study of chronic neutrophilic leukemia in the United States. 61
32541648 2020
8
Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy. 61
31844143 2020
9
Chronic neutrophilic leukemia presenting as secondary gout: Report of a rare myeloproliferative disorder. 61
32445325 2020
10
[Fatal intracerebral hemorrhage in a patient with chronic neutrophilic leukemia: About one case and literature review]. 61
32362366 2020
11
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. 61
31880950 2020
12
[Ruxolitinib in the treatment of two cases of chronic neutrophilic leukemia]. 61
32135644 2020
13
Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management. 61
31769070 2020
14
An atypical chronic neutrophilic leukemia patient harboring ASXL1 and NRAS mutations associated with monoclonal plasma cell dyscrasia presenting as hemopericardium. 61
32052135 2020
15
T618I CSF3R mutations in chronic neutrophilic leukemia induce oncogenic signals through aberrant trafficking and constitutive phosphorylation of the O-glycosylated receptor form. 61
31848046 2020
16
[Analysis of Clinical Features and Prognosis of Patients with Chronic Neutrophil Leukemia]. 61
32027257 2020
17
A case of paraneoplastic hyperleukocytosis closely mimicking chronic neutrophilic leukemia. 61
32362636 2020
18
CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib. 61
32577374 2020
19
Clonal evolution in a chronic neutrophilic leukemia patient. 61
31076019 2019
20
[Chronic neutrophilic leukemia with CSF3R mutation and concurrent multiple myeloma: one case report]. 61
32023742 2019
21
Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. 61
31697825 2019
22
Molecular response of CSF3R T618I harboring chronic neutrophilic leukemia after induction chemotherapy linked to cord blood transplantation. 61
31240470 2019
23
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. 61
31366621 2019
24
Phospho serine and threonine analysis of normal and mutated granulocyte colony stimulating factor receptors. 61
30967555 2019
25
Chronic Neutrophilic Leukemia: Current and Future Perspectives. 61
30581159 2019
26
Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors. 61
29977015 2019
27
Genetic studies in the evaluation of myeloproliferative neoplasms. 61
30573049 2019
28
Novel treatment strategies for myeloproliferative neoplasms. 61
31597841 2019
29
Neutrophilic leukemoid reaction associated with plasma cell neoplasm mimicking chronic neutrophilic leukemia. 61
30630849 2019
30
[Ruxolitinib for chronic neutrophilic leukemia: a case report and literature review]. 61
30612407 2018
31
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. 61
30348809 2018
32
Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. 61
30458320 2018
33
Colony-stimulating Factor 3 Receptor Mutated Chronic Neutrophilic Leukemia: A Rare Case Report. 61
30473959 2018
34
Septic Shock Predisposed by an Underlying Chronic Neutrophilic Leukemia with an Atypical Presentation; A Case Report. 61
30687064 2018
35
Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. 61
29512199 2018
36
Chronic neutrophilic leukemia, an extremely rare cause of neutrophilia in childhood: Cure with hematopoietic stem cell transplantation. 61
29676020 2018
37
CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia. 61
29932212 2018
38
Chronic neutrophilic leukemia. 61
29473201 2018
39
Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. 61
28762112 2018
40
Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review. 61
29587671 2018
41
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. 61
29449543 2018
42
Chronic neutrophilic leukemia: new science and new diagnostic criteria. 61
29440636 2018
43
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. 61
29426921 2018
44
Chronic neutrophilic leukemia. 61
29686565 2018
45
Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq. 61
29025591 2017
46
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. 61
28983816 2017
47
Enhanced MAPK signaling is essential for CSF3R-induced leukemia. 61
28031554 2017
48
Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function. 61
28652245 2017
49
Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. 61
28302714 2017
50
Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. 61
28209656 2017

Variations for Chronic Neutrophilic Leukemia

Expression for Chronic Neutrophilic Leukemia

Search GEO for disease gene expression data for Chronic Neutrophilic Leukemia.

Pathways for Chronic Neutrophilic Leukemia

GO Terms for Chronic Neutrophilic Leukemia

Cellular components related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynapse GO:0098794 8.8 SEPTIN11 JAK2 ABL1

Biological processes related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin organization GO:0006325 9.71 TET2 KMT2A JAK2 ASXL1
2 T cell activation involved in immune response GO:0002286 9.48 IFNA2 IFNA1
3 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.46 IFNA2 IFNA1
4 histone H3-K4 trimethylation GO:0080182 9.43 TET2 KMT2A
5 positive regulation of actin cytoskeleton reorganization GO:2000251 9.37 CSF3 ABL1
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.33 JAK2 CSF3 ABL1
7 natural killer cell activation involved in immune response GO:0002323 9.32 IFNA2 IFNA1
8 negative regulation of cell-cell adhesion GO:0022408 9.26 JAK2 ABL1
9 B cell proliferation GO:0042100 9.13 IFNA2 IFNA1 ABL1
10 cytokine-mediated signaling pathway GO:0019221 9.02 JAK2 IFNA2 IFNA1 CSF3R CSF3

Molecular functions related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 type I interferon receptor binding GO:0005132 8.62 IFNA2 IFNA1

Sources for Chronic Neutrophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....